



BMP-2 and TGF- β 1 inhibit the expression of the pro-inflammatory cytokine IL-34 in rheumatoid arthritis synovial fibroblasts

Marguerite Chemel, Régis Brion, Aude Segaliny, Audrey Lamora, Céline Charrier, Bénédicte Brulin, Yves Maugars, Benoit Le Goff, Dominique Heymann, Franck Verrecchia

► To cite this version:

Marguerite Chemel, Régis Brion, Aude Segaliny, Audrey Lamora, Céline Charrier, et al.. BMP-2 and TGF- β 1 inhibit the expression of the pro-inflammatory cytokine IL-34 in rheumatoid arthritis synovial fibroblasts. American Journal of Pathology, 2017, 187 (1), pp.156-162. 10.1016/j.ajpath.2016.09.015 . inserm-01466118

HAL Id: inserm-01466118

<https://inserm.hal.science/inserm-01466118>

Submitted on 13 Feb 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

BMP-2 and TGF- β 1 inhibit the expression of the pro-inflammatory cytokine IL-34 in rheumatoid arthritis synovial fibroblasts

Marguerite Chemel,^{*†‡} Regis Brion,^{*†} Aude-Isabelle Segaliny,^{*†} Audrey Lamora,^{*†}
Celine Charrier,^{*†} Benedicte Brulin,^{*†} Yves Maugars,[‡] Benoit Le Goff,^{*†‡} Dominique
Heymann,^{*†‡§} and Franck Verrecchia,^{*†}

From, ^{*}INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France; [†]Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; [‡]CHU Hôtel Dieu, Nantes, France; [§]Department of Oncology and Metabolism, INSERM European Associated Laboratory, « Sarcoma REsearch Unit » The Medical School, University of Sheffield, UK

Number of text pages: 8, **number of tables:** 1, **number of figures:** 3

Running head: BMP-2 and TGF- β inhibit IL-34 expression in RA

Grants: AI Segaliny received a PhD fellowship from the Region des Pays de la Loire (CIMATH II Research Program) and A Lamora from the Ecole de l'INSERM and Fondation Bettencourt Schueller.

Address correspondence to: Dominique Heymann or Franck Verrecchia, INSERM UMR957, Faculté de Médecine, 1 rue Gaston Veil, 44000 Nantes, France, Phone: +33 240412895, Fax: +33 240412860, E-mail: dominique.heymann@univ-nantes.fr or franck.verrecchia@inserm.fr

Potential conflicts of interest: NO

Abstract

Interleukin-34 (IL-34) is a pro-inflammatory cytokine implicated in rheumatoid arthritis (RA). The present study aimed to assess the IL-34 expression in response to two members of the TGF- β family, TGF- β 1 and BMP-2, in synovial fibroblasts from RA patients. IL-34, TGF- β 1 and BMP-2 productions were measured in patient synovial fluids by ELISA. IL-34 mRNA levels were quantified by qPCR in human synovial fibroblasts and murine mesenchymal stem cells (mMSCs). Pharmacological inhibitions were used to determine the involvement of ALK1 and ALK5 downstream TGF- β 1 and BMP-2. IL-34, TGF- β 1 and BMP-2 were expressed in synovial fluids from RA patients. We found a significant correlation between IL-34 and TGF- β 1 expressions. Levels of both IL-34 and TGF- β 1 were thus correlated with the total leukocyte counts in the synovial fluids. TGF- β 1 and BMP-2 decreased IL-34 expression in the synovial fibroblasts or in mMSC in a dose- and time-dependent manner through respectively ALK5 and ALK1 pathways. In addition, TGF- β 1 antagonized TNF α -induced IL-34 gene expression. This work identifies TGF- β 1 and BMP-2 as potent inhibitors of IL-34 expression in RA synovial fibroblasts. These cytokines, as upstream inhibitors of IL-34, may thus contribute to antagonize inflammation and bone erosions in RA.

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease characterised by a chronic inflammation of the synovial tissue that leads to progressive joint destruction.¹ Among the cells located in the inflamed joint, synovial fibroblasts are crucial players driving inflammation and bone erosion.²

IL-34,³ basically described as promoting monocyte proliferation and survival, and osteoclast differentiation,⁴ is expressed by synovial fibroblasts of RA patients. Its expression, correlated with inflammation, the number of leucocytes and the severity of the synovitis, is upregulated by $\text{TNF}\alpha$ and $\text{IL-1}\beta$.⁵

TGF- β s and BMPs, are proteins involved in control of many biological processes such as cell proliferation and differentiation. The importance of TGF- β for the pathogenesis of arthritis is emphasized by several observations made in patients and in animal models.⁶ TGF- β 1 and its receptors T β RII were detected at high levels in the synovial fibroblasts of RA patients and in RA synovial fluids.⁷⁻⁹ In this context, numerous studies have demonstrated the beneficial effects of TGF- β in RA.⁶ TGF- β 1 suppresses acute and chronic arthritis in experimental models, and a strong increase of TGF- β 1 expression was measured in the remission state of disease.¹⁰ Much less data exist regarding the role of BMP during the pathogenesis of RA. However, increasing evidences suggest that BMPs, known to play a crucial role in skeletal development, could play a major role in RA to restore function of synovial joints.¹¹ In this study, we hypothesised that IL-34 expression could be modulated by TGF- β 1 and BMP-2.

Materials and Methods

Synovial fluid

Synovial fluids were obtained in the Rheumatologist Unit of Nantes University Hospital. The clinical characteristics of patients are summarized in Table 1. The study was approved by the local ethic committee and by the French Research Ministry (n° 2008-402). IL-34, BMP-2 and TGF- β levels were measured in synovial fluids by ELISA assay (antibodies-online-GmbH for IL-34, R&D System for BMP-2 and TGF- β 1).

Cell cultures

Synovial fibroblasts, obtained from the synovial tissue of RA patients, and mouse C3H10T1/2 mesenchymal stem cells (MSCs), purchased from the ATCC (CCL-226), were cultured in alpha-MEM (Invitrogen) supplemented with 10% fetal bovine serum (Hyclone Perbio). TGF- β 1 and BMP-2 were purchased from R&D System. ALK1 inhibitor (LDN 212854) and ALK5 inhibitor (SB431542) were purchased from Sigma.

Reverse transcription PCR analysis

RNA was extracted using the NucleoSpin RNAII kit (Macherey-Nagel). One microgram of total RNA was used for first strand cDNA synthesis using ThermoScript RT-PCR System (Invitrogen, Carlsbad, CA, USA). DNase I treatment (25 units, 15 min) of total RNA was performed to eliminate genomic contamination.. Real-time PCR was performed with a Chromo4 instrument (Biorad) using SYBR Green Supermix reagents (Biorad). Primer sequences were described in Table 2.

Western blot

Western Blot analyses were performed as previously described.⁴ Briefly, cells were lysed in a lysis buffer (SDS 1%, Tris pH 7.4 10mM, Sodium orthovanadate 1 mM) and protein concentration was determined by BCA kit (Sigma). Twenty micrograms of total protein in Laemmli buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.001% bromophenol blue) were separated by SDS-polyacrylamide gel electrophoresis, and transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). Membranes were immunoblotted with anti phospho-Smad3 and Smad3 (Millipore), or phospho-Smad1/5 and Smad1/5 (Cell Signaling) antibodies.

Confocal microscopy experiments

Cell cultures, treated with TNF- α (10 ng/mL), and TGF- β 1 (10 ng/mL) for 24h, were fixed and stained with the primary antibody against IL-34 (Diacclone, INSERM UMR 957) as previously described.¹²

Statistical analysis

The Spearman test was use to look for a correlation between IL-34 expression and the diagnosis. Kruskal Wallis test was used to assess the change in gene expression. An alpha level of 0.05 was chosen to assess statistical significance.

Results

Increased production of IL-34 and TGF- β 1 in RA synovial fluids

The expression of IL-34, TGF- β 1 and BMP-2 was detected in synovial fluids of RA patients (n=44, Figure 1A). IL-34 and TGF- β 1 levels were associated with the inflammation intensity measured by the leukocyte counts (Figure 1B, respectively $r=0.4$, $p=0.01$ and $r=0.36$, $p=0.02$). A positive correlation between IL-34 and TGF- β levels in synovial fluids was found (Figure 1C, $r=0.63$, $p<0.0001$). No significant association was found between BMP-2 and IL-34 expression (Figure 1C), and between BMP-2 and the inflammation intensity measured by the leukocyte counts (Figure 1B).

TGF- β 1 and BMP-2 decrease IL-34 expression in human RA synovial fibroblasts and mMSCs

The IL-34 mRNA steady-state levels following TGF- β 1 or BMP-2 treatment were next investigated by quantitative RT-PCR. Both TGF- β 1 (10 ng/ml) and BMP-2 (100 ng/ml) significantly decreased IL-34 mRNA steady state levels in synovial fibroblasts from three different RA patients (Figure 2A, left panel) and in other mesenchymal cells such as mMSC (Figure 2A, right panel). The decrease of IL-34 expression in the presence of TGF- β 1 or BMP-2 resulted in a time- and dose-dependent inhibition of IL-34 mRNA (Figure 2B and 2C). Only TGF- β 1 down regulated M-CSF in human synovial cells (Figure 2D).

ALK5 and ALK1 receptors are involved in the inhibition of IL-34 expression driven by TGF- β 1 or BMP-2

Since BMP-2 and TGF- β 1 preferentially signal from the membrane to the nucleus via respectively ALK1 and ALK5 receptors, we used validated chemical inhibitors of ALK1 (LDN 212854) and ALK5 (SB431542). We first demonstrated that BMP-2 and TGF- β 1 stimulate respectively the ALK1/Smad1-5 and the ALK5/Smad2-3 signaling pathways (Figure 3A, left panels). We secondly demonstrated that LDN 212854 and SB431542 specifically inhibit the ALK1/Smad1-5 and the ALK5/Smad2-3 signaling pathways in mMSC (Figure 3A, middle and right panels). Then, we observed that ALK1 and ALK5 inhibitors block the response to respectively BMP-2 and TGF- β 1 in mMSC (Figure 3B). Similarly, in fibroblasts of two RA patients (P1 and P2), we observed that the ALK5 inhibitor reverses the effect of TGF- β 1 on IL-34 gene expression and that the ALK1 inhibitor partially reverses the effect of BMP-2 (Figures 3C and 3D). Interestingly, TGF- β 1 stimulates BMP-2 mRNA steady state level in RA synovial fibroblasts (Supplemental Figures S1).

TGF- β 1 inhibits IL-34 expression in inflammatory conditions

Since pro-inflammatory cytokines such as IL-1 β and TNF- α play a crucial role in RA and since we previously demonstrated that TNF- α induces IL-34 expression,⁵ we studied the effect of TGF- β 1 and BMP-2 in inflammatory conditions. To this end, cells were treated with TNF- α . As shown in Figure 4, TGF- β 1 (Figure 4A) and BMP-2 (Figure 4B) significantly reduce the response of the cells to TNF- α . Specifically, TGF- β 1 and BMP-2 repress the basal levels of IL-34 rather than directly the response of the cells to TNF- α . Confocal microscopy analyses confirmed that IL-34 production

paralleled the modulation of IL-34 mRNA (Figure 4C). Specifically, TNF- α treatment resulted in an increase of IL-34 production in contrast to TGF- β 1 which markedly reduced it. To ascertain this results on protein level, we quantified the IL-34 production by ELISA approach. As shown in Figure 4D,

Discussion

Scientific studies have focused on the complex role of cytokines in the development and progression of RA. During the last decade, it has been demonstrated that pro-inflammatory cytokines such as TNF- α or IL-1 β play a crucial role in the pathophysiology of RA. These cytokines indeed promote inflammation and osteoclastogenesis in the arthritic joint leading to the destruction of cartilage and bone.¹³ In this context, neutralizing TNF- α has proven successful to control RA in many cases.¹³ During the last years, new pro-inflammatory cytokines, such as IL-32, IL-34 or IL-35 have been studied for their role in the pathogenesis RA. Recently, we demonstrated that IL-34, as a downstream effector of TNF α and IL-1 β , is involved in the pathogenesis of RA.⁵

A better understanding of the mechanisms regulating the expression of this cytokine should allow to development new therapeutic approaches. We identified here two cytokines, BMP-2 and TGF- β 1 able to inhibit IL-34 gene expression. We specifically demonstrated that TGF- β 1 and BMP-2 inhibit IL-34 expression in synovial fibroblasts and in mMSC via respectively the ALK1 and ALK5 receptors. BMP-2 may indirectly reduce bone resorption by inhibiting the expression of IL-34 known to be able to stimulate osteoclastogenesis.⁴ BMP-2 could thus prevent the bone degradation in RA by directly stimulating bone formation and indirectly by inhibiting bone resorption.

The role of TGF- β , identified as a pro-fibrotic agent in many tissues,¹⁴ remains unclear in RA. It appears that this cytokine, involved in the pannus development,⁹ could act as a pro-fibrotic agent in RA. In this context, some authors demonstrated the beneficial effects of TGF- β in RA.⁶ Indeed, systemic administration of TGF- β 1

antagonized the development of polyarthritis in susceptible rats.¹⁵ In addition, the inhibition of TGF- β signaling increased the clinical severity of arthritis in collagen-induced arthritis model.¹⁰

To resume, we describe for the first time, the regulation of IL-34 expression by BMP-2 and TGF- β in the context of inflammatory stimulation. Such control loops appear to play a key role in the control of inflammation and bone resorption in RA (Figure 5). Future pre-clinical investigations are necessary to assess the potential clinical application of targeting IL-34 in RA. In addition, since BMP-2 and TGF- β 1 have pleiotropic effects in different cells types, targeting these cytokines in RA need more investigations to define therapeutic treatments.

References

1. Klareskog L, Catrina AI, Paget S: Rheumatoid arthritis. *Lancet* 2009, 373:659-672
2. Bartok B, Firestein GS: Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. *Immunol Rev* 2010, 233:233-255
3. Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT: Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. *Science* 2008, 320:807-811
4. Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, Gouin F, Duplomb L, Heymann D: Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. *J Pathol* 2010, 221:77-86
5. Chemel M, Le Goff B, Brion R, Cozic C, Berreur M, Amiaud J, Bougras G, Touchais S, Blanchard F, Heymann MF, Berthelot JM, Verrecchia F, Heymann D: Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. *Ann Rheum Dis* 2012, 71:150-154

6. Pohlers D, Brenmoehl J, Löffler I, Müller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G: TGF- β and fibrosis in different organs, Molecular pathway imprints. *Biochim Biophys Acta* 2009, 1792:746-756
7. Pohlers D, Beyer A, Koczan D, Wilhelm T, Thiesen HJ, Kinne RW: Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts. *Arthritis Res Ther* 2007, 9:R59
8. Cho ML, Min SY, Chang SH: Transforming growth factor beta1 down-regulates TNFalpha-induced RANTES production in rheumatoid synovial fibroblasts through NF-kappaB-mediated transcriptional repression. *Immunol Lett* 2006, 105:159-166
9. Müssener A, Funa K, Kleinau S, Klareskog L: Dynamic expression of transforming growth factor-betas (TGF-beta) and their type I and type II receptors in the synovial tissue of arthritic rats. *Clin Exp Immunol* 1997, 107:112-119
10. Schramm C, Kriegsmann J, Protschka M, Huber S, Hansen T, Schmitt E, Galle PR, Blessing M: Susceptibility to collagen-induced arthritis is modulated by TGFbeta responsiveness of T cells. *Arthritis Res Ther* 2004, 6:R114-119
11. Lories RJ, Luyten FP, Bone morphogenetic protein signaling in joint homeostasis and disease. *Cytokine Growth Factor Rev* 2005, 16:287-298

12. Segaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D: Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. *Int J Cancer* 2005, 137:73-85
13. Venkatesha SH, Dudics S, Acharya B, Moudgil KD: Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. *Int J Mol Sci* 2014, 16:887-906
14. Verrecchia F, Mauviel A, Farge D: Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. *Autoimmun Rev* 2006, 5:563-569
15. Brandes ME, Allen JB, Ogawa Y, Wahl SM: Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. *J Clin Invest* 1991, 87:1108-1113

Figure legends

Figure 1. *IL-34, TGF- β 1 and BMP-2 production in synovial fluid.*

Synovial fluid samples of RA patients were collected (n=44). **A:** Detection of IL-34, TGF- β 1 and BMP-2 in synovial fluids. Each plot represents an individual sample. **B:** Correlation between levels of IL-34, TGF- β 1, BMP-2 and total leukocyte count (mean \pm SD, each plot represents an individual sample). **C:** Correlation between levels of IL-34 and TGF- β , and of IL-34 and BMP-2. Each plot represents an individual sample.

Figure 2. *BMP-2 and TGF- β 1 repress IL-34 mRNA expression.*

A: Synovial fibroblasts from three patients (left panel, P1 to P3) and mMSC (right panel) (means \pm S.D., n=3, *p<0.05, ***p<0.001) were incubated in presence or absence of BMP-2 (100 ng/mL) or TGF- β 1 (10 ng/mL) for 8h. IL-34 mRNA levels were determined by RT-qPCR.

B: mMSC (means \pm S.D., n=3, *p<0.05, ***p<0.001) were stimulated with BMP-2 (0, 25, 50, 75, 100 or 200 ng/mL) for 8h (left panel), or with 100 ng/mL BMP-2 for either 8, 24 or 48h (right panel). IL-34 mRNA levels were determined by qRT-PCR.

C: mMSC (means \pm S.D., n=3 *p<0.05, **p<0.01, ***p<0.001, ***p<0.001) were stimulated with TGF- β 1 (0, 0.1, 1, 2.5, 5, or 10 ng/mL) for 8h (left panel), or with 10 ng/mL TGF- β 1 for either 8, 24 or 48h (right panel). IL-34 mRNA levels were determined by qRT-PCR.

D: Synovial fibroblasts (P1, P2, P3) or mMSC (means \pm S.D., n=3) were stimulated with BMP-2 (100 ng/mL) or TGF- β 1 (10 ng/mL) for 8h. M-CSF mRNA levels were determined by qRT-PCR.

Figure 3. *ALK5 and ALK1 receptors are involved in the inhibition of IL-34 expression driven by TGF β 1 or BMP-2*

A: mMSC were incubated with SB431542 (10 μ M) or LDN212854 (10 nM). 1h after, BMP-2 (100 ng/mL) or TGF- β 1 (10 ng/mL) was added for 1h. Phospho-Smad levels were detected by Western Blot. Histogramms represent the ratio of the phosphoSmad to the total Smad protein levels.

B: mMSC were incubated with SB431542 (10 μ M) or LDN212854 (10 nM). 1h after, BMP-2 (100 ng/mL) or TGF- β 1 (10 ng/mL) was added for 8h. IL-34 mRNA levels were determined by RT-qPCR. (means \pm S.D., n=3, *p<0.05, ***p<0.001).

C and D: synovial fibroblasts from two patient (P1 and P2) were incubated with SB431542 (10 μ M, C) or LDN212854 (10 nM, D). 1h after, BMP-2 (100 ng/mL) or TGF- β 1 (10 ng/mL) was added for 8h. IL-34 mRNA levels were determined by RT-qPCR.

Figure 4. *TGF- β 1 antagonizes TNF- α -induced IL-34.*

A and B: Synovial fibroblasts from three patients (P1 to P3) were stimulated with TNF- α (10 ng/mL) together with TGF- β 1 (A, 10 ng/mL) or BMP-2 (B, 100 ng/mL) for 8h. IL-34 mRNA levels were determined by RT-qPCR.

C: Synovial fibroblasts cultured on labtek chamber slides were treated with TNF α (10 ng/mL), TGF- β 1 (10 ng/mL) or both for 24 h. IL-34 expression (pink), and nuclei stained by Hoechst reagent (blue) were observed by confocal microscopy. A representative experiment (X40) is shown.

D: ELISA

Figure 5. Schematic representation of the regulation of IL-34 expression in RA




Table 1 : Characteristics of patients included in the study

| Leukocyte number/mm3 | DMARS/Biotherapy | Corticosteroids | Sex | Age (yrs) | Duration of disease (months) | Antibody status | | CRP(mg/l) |
|------------------------------|------------------------|-----------------|-----|-----------|------------------------------|-----------------|----|-----------|
| | | | | | | ACPA | RF | |
| High inflammatory fluids | | | | | | | | |
| 27000 | Abatacept | + | F | 59 | 360 | + | + | ND |
| 22500 | Tocilizumab | + | M | 59 | 408 | - | + | 45 |
| 21000 | Tocilizumab/MTX | + | M | 65 | 3 | + | + | 217 |
| 33600 | Tocilizumab | - | M | 53 | 132 | + | + | <5 |
| 30900 | Tocilizumab/MTX | + | M | 71 | 36 | - | - | <5 |
| 25320 | Leflunomid | + | M | 42 | 96 | + | - | 39.8 |
| 44100 | MTX | + | M | 40 | 10 | - | + | 109 |
| 48000 | - | + | F | 71 | 456 | - | ND | ND |
| 43080 | - | - | F | 74 | 84 | - | - | ND |
| 39900 | - | - | M | 77 | 36 | + | + | 64 |
| 38300 | - | - | F | 74 | 72 | - | - | 23 |
| 28000 | - | - | F | 81 | 120 | + | + | 33 |
| 22080 | - | + | M | 52 | 108 | + | + | 59 |
| Moderate inflammatory Fluids | | | | | | | | |
| 14200 | Abatacept | + | F | 84 | 8 | + | + | 95 |
| 10710 | Tocilizumab | + | F | 66 | 216 | + | + | 30 |
| 19920 | Rituximab | + | F | 55 | 228 | - | + | ND |
| 17000 | Adalimumab/MTX | + | M | 53 | 144 | ND | + | 62 |
| 13000 | MTX | + | F | 66 | ND | ND | ND | ND |
| 11600 | MTX/Hydroxychloroquine | + | F | 64 | 1 | + | = | 47 |
| Low inflammatory Fluids | | | | | | | | |
| 2280 | Abatacept/MTX | + | F | 72 | >200 | + | + | 6 |
| 9120 | Tocilizumab | + | F | 66 | 48 | - | - | 31 |
| ND | Tocilizumab/MTX | + | F | 61 | 240 | + | + | ND |
| 5600 | Tocilizumab | + | F | 44 | 108 | - | + | 104 |
| 2070 | Adalimumab/MTX | - | F | 43 | 192 | + | - | 10 |
| 6600 | Adalimumab | + | M | 64 | 300 | + | + | 7.9 |
| 1700 | Adalimumab/MTX | + | M | 51 | 132 | + | + | <3 |
| 1080 | Infliximab/MTX | ND | M | 60 | 96 | + | + | ND |
| 5280 | Infliximab/MTX | - | M | 50 | 160 | + | + | 4 |
| 3600 | Infliximab/MTX | + | F | 51 | 84 | + | + | 58 |
| ND | MTX | + | F | 73 | 204 | + | + | ND |
| ND | MTX | - | M | 48 | 36 | + | + | 15 |
| 7440 | MTX | + | F | 52 | 20 | + | - | ND |
| 7420 | MTX | + | F | 83 | 36 | + | + | 24.7 |
| 4500 | MTX | + | F | 37 | ND | - | - | ND |
| 3500 | MTX | + | F | 76 | ND | ND | + | ND |
| 9000 | - | + | F | 48 | 144 | + | + | ND |
| 1200 | - | - | F | 68 | 140 | - | - | 29.8 |
| 4800 | - | + | F | 73 | 9 | + | + | 30 |
| 1380 | - | + | F | 45 | 120 | + | + | 182 |
| 2640 | - | + | F | 45 | 120 | + | + | 182 |
| 1500 | ND | ND | F | 55 | ND | ND | ND | ND |
| 4590 | - | - | M | 71 | 4 | - | - | 87.7 |
| 9120 | - | - | M | 46 | 1 | + | + | 35 |
| ND | ND | ND | F | 59 | ND | ND | ND | ND |

MTX: Methotrexate; RF: Rheumatoid Factor, ACPA: Anti-citrullinated Protein Antibody

Table 2: Sequences of primers

| | |
|----------------------|--------------------------------|
| human IL34 sens | 5'-CTTACGAGGGGGTGTTCAGA-3' |
| human IL34 antisens | 5'-ACCAAGACCCACAGATACCG-3' |
| mouse IL34 sens | 5'-GGACACACTTCTGGGGACA-3' |
| mouse IL34 antisens | 5'-CCAAAGCCACGTCAAGTAGG-3' |
| human GAPDH sens | 5'-TGGGTGTGAACCATGAGAAGTATG-3' |
| human GAPDH antisens | 5'-GGTGCAGGAGGCATTGCT-3' |
| mouse Hprt sens | 5'-TCCTCCTCAGACCGCTTTT-3' |
| mouse Hprt antisens | 5'-CCTGGTTCATCATCGCTAATC-3' |

A**B****C****Figure 1**




Figure 2





Figure 3



B






Figure 4



Figures 5



Supplemental Figures S1

Supplemental Figure legends

Supplemental Figures 1. *BMP-2 and TGF- β 1 effect on TGF- β 1 and BMP-2 mRNA expression*

RA synovial fibroblast were incubated with BMP-2 (100 ng/mL) or TGF- β 1 (10 ng/mL) for 8h. TGF- β 1 (left panel) or BMP-2 (right panel) mRNA levels were determined by qRT-PCR.